Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease

Al‐Janabi, Ali; Littlewood, Zoe; Griffiths, C.E.M.; Hunter, Hamish J.A.; Chinoy, Hector; Moriarty, C; Yiu, Zenas Z N; Warren, Richard B

doi:10.1111/bjd.20479

Cited by 30 publications

(28 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our group found that of 120 participants receiving biologics or oral immunomodulators for psoriasis or other IMID, 85% had detectable anti-SARS-CoV-2 immunoglobulin following the first dose of BioNTech/Pfizer and AstraZeneca vaccines. 59 Furthermore, relative to biologics, there was a reduced odds of anti-spike IgG production with oral immunomodulators (OR 0.18, 95% CI 0.06–0.59) and reduced odds of total anti-spike immunoglobulin with combined biologic and oral immunomodulators (OR 0.06, 95% CI 0.01–0.80). 59 A strength of this study was that it identified those with prior infection (including asymptomatic infection) by measuring anti-nucleocapsid antibodies present following infection but not vaccination.…”

Section: Infectionmentioning

confidence: 97%

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management

Al‐Janabi¹,

Yiu²

2022

PTT

View full text Add to dashboard Cite

Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In addition to treatment effectiveness, it is important to define and understand the long-term risks of biologic therapy in order to guide therapy selection and minimise these risks for patients where possible. This review article summarises available evidence from trial data, observational studies and pharmacovigilance registries to explore key long-term risks of biologic treatment, and how these risks might be managed in clinical practice.

show abstract

Section: Infectionmentioning

confidence: 97%

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management

Al‐Janabi¹,

Yiu²

2022

PTT

View full text Add to dashboard Cite

show abstract

“…15 Although the prospective randomized studies for the currently available mRNA and adenovirus COVID-19 vaccines excluded patients on immunomodulatory medications, several groups have published case series of patients with IMID who have been vaccinated (Tables I and II). [16][17][18][19][20][21][22][23][24][25][26][27][28] These data suggest that patients receiving biologics for the treatment of inflammatory and autoimmune disease can safely receive, and are able to mount a detectable immune response to, the COVID-19 vaccines, with a few notable exceptions.…”

Section: Safety Of Covid-19 Vaccines In Patients With Imidmentioning

confidence: 90%

“…In small case series, patients receiving these therapies have produced detectable immune responses with no reported cases of reduced antibody response thus far. 25,27…”

Section: Il-23 Inhibitorsmentioning

confidence: 99%

COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence

Wack

Patton

Ferris

2021

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Dermatologists diagnose and treat many immune-mediated inflammatory diseases (IMID). Understanding the inherent immune dysregulation of these diseases as well as the additional disruption that comes as a result of IMID treatments has been important during the COVID-19 pandemic. With vaccines becoming widely available, dermatologists need to be familiar with the risks and benefits of vaccination in these patients, particularly those taking biologics, in order to have informed discussions with their patients. In this review, we present the current evidence related to COVID-19 vaccine safety and efficacy in patients with IMID and review existing recommendations for vaccination against SARS-CoV-2. Given the current evidence, there is minimal concern that these patients are at any greater risk of harm from COVID-19 vaccination compared to healthy controls. For most, the benefit of avoiding severe COVID-19 through vaccination will outweigh the theoretical risk of these vaccines. A question that is still outstanding is whether patients on biologics will generate a sufficient immune response to the vaccine, which may be dependent on the specific biologic therapy and indication being treated. This underscores the importance of following patients with IMID after vaccination to determine the safety, efficacy, and duration of the vaccine in this population.

show abstract

“…Four other cohort studies on immune responses against SARS-CoV-2 vaccination among patients with AIIRD further confirmed a lower seroconversion rate in those being treated with MTX [14,19,21,31]. However, a larger cohort study by Boekel et al demonstrated a significantly lower rate of seroconversion in AIIRD patients without previous SARS-CoV-2 infection as compared to healthy controls following the first dose of SARS-CoV-2 vaccination, while the seroconversion rate reached similar after the second dose.…”

Section: Methotrexatementioning

confidence: 92%

The Use of COVID-19 Vaccines in Patients with SLE

et al. 2021

View full text Add to dashboard Cite

Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease

Cited by 30 publications

References 8 publications

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management

COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence

The Use of COVID-19 Vaccines in Patients with SLE

Contact Info

Product

Resources

About